UBS initiated coverage of Penumbra (PEN) with a Buy rating and $305 price target The firm sees the company’s ongoing new product launch cycle delivering “clear line of sight” into sales and earnings upside drivers over the near-to-medium term. The shares should continue to trade at a premium versus its high-growth Smid-Cap medical technology peers given their “top-tier growth and margin profile,” the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.